Belite Bio
BLTE

Belite Bio (BLTE) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
HC Wainwright & Co.MaintainedBuy$245.00Oct 15, 2026
MizuhoMaintainedOutperform$234.00 from $220.00Sep 9, 2026
HC Wainwright & Co.MaintainedBuy$245.00 from $214.00Sep 8, 2026
Canaccord GenuityInitiated CoverageBuy$303.00Sep 4, 2026
Cantor FitzgeraldMaintainedOverweight$270.00 from $266.00Aug 14, 2026
Morgan StanleyMaintainedOverweight$206.00 from $201.00Aug 14, 2026
HC Wainwright & Co.MaintainedBuy$214.00 from $200.00Aug 12, 2026
HC Wainwright & Co.MaintainedBuy$200.00Jun 15, 2026
MizuhoMaintainedOutperform$215.00 from $223.00May 26, 2026
HC Wainwright & Co.MaintainedBuy$200.00May 21, 2026
HC Wainwright & Co.MaintainedBuy$200.00Apr 22, 2026
HC Wainwright & Co.MaintainedBuy$200.00Apr 13, 2026
Cantor FitzgeraldMaintainedOverweight$266.00 from $200.00Mar 3, 2026
Morgan StanleyMaintainedOverweight$201.00 from $191.00Mar 3, 2026
HC Wainwright & Co.MaintainedBuy$200.00 from $185.00Mar 3, 2026
HC Wainwright & Co.MaintainedBuy$185.00Jan 28, 2026
B of A SecuritiesInitiated CoverageBuy$195.00Jan 26, 2026
Morgan StanleyInitiated CoverageOverweight$191.00Jan 6, 2026
MizuhoUpgradedNeutral → Outperform$194.00 from $105.00Dec 2, 2025
HC Wainwright & Co.MaintainedBuy$185.00 from $98.00Dec 1, 2025

Frequently asked questions

  • What is the latest analyst rating on BLTE?

    On Oct 15, 2026, HC Wainwright & Co. maintained Belite Bio at Buy with a price target of $245.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.